

Special Issue

Vaccination Progress in COVID-19 and HPV

Message from the Guest Editor

Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the COVID-19 pandemic. Over a year into the biggest vaccination campaign in history, more than 12.7 billion doses have been administered across 184 countries. The human papillomavirus (HPV) vaccine helps to protect against cancers caused by HPV, including [cervical cancer](#), some [mouth and throat cancers](#), and some cancers of the anal and genital areas. The current global COVID-19 pandemic threatens to derail the uptake of HPV vaccination in low- and lower-middle income countries, which has a major impact on the World Health Organization cervical cancer elimination strategy, which is dependent on HPV vaccination as well as cervical cancer screening and treatment. This Special Issue welcomes submissions across the broadest interpretation of these issues.

Guest Editor

Dr. Wangnan Cao

Department of Social Medicine and Health Education, School of Public Health, Peking University Health Science Center, Beijing 100191, China

Deadline for manuscript submissions

closed (30 April 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/149166

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).